

Chlamydia infections Market is Predicted to Exhibit Remarkable Growth by 2032, Analyzes DelveInsight

Chlamydia Infections Market Size in expected to Grow

LAS VEGAS, NEVADA, UNITED STATES, March 19, 2024 /EINPresswire.com/ -- DelveInsight's "Chlamydia Infections Market Insights, Epidemiology, and Market Forecast-2032" report offers an in-depth understanding of the Chlamydia, historical and forecasted epidemiology as well as the Chlamydia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.



Some of the key facts of the Chlamydia Market Report:

- The Chlamydia market size was valued approximately USD 59 million in 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
- The cases in various nations were added to determine the total diagnosed incident cases in the 7MM. 3,453,387 incident cases of 7MM chlamydia were diagnosed in total in 2021; the majority of these cases were found in the United States. 1,138,482 cases were reported from the EU5 countries, compared to 327,918 cases from Japan in 2021
- Key Chlamydia Companies: Evofem Biosciences, QureTechBio, Vault Pharma, Aeterna Zentaris, ActivBiotics Pharma, LLC, Endo Pharma, and others
- Key Chlamydia Therapies: EVO100, Chlamydia Infection blockers (CIBs), VPI-201, Salmonella-Based Vaccine, Rifalazil, PRO 2000/5, and others.
- February 2024: IVIEQ Therapeutics Inc. announced a study of Phase 2 clinical trials for IVIEW-1201. A Phase 2, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of IVIEW-1201 (1.0% Povidone-Iodine) Gel Forming Ophthalmic Solution Compared to Placebo in the Treatment of Adenoviral Conjunctivitis.
- January 2024: Evofem Inc. announced a study of Phase 3 clinical trials for EVO100. This study will evaluate whether EVO100 vaginal gel prevents the sexual transmission of CT and GC infection.

To know in detail about the Chlamydia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here @ [Chlamydia Market Forecast](#)

Chlamydia Overview

The most prevalent bacterial STI is chlamydial infection, which is brought on by Chlamydia trachomatis. The highest incidence of chlamydial infection in women occur between the ages of 15 and 24. Age is a powerful predictor of risk for chlamydial infections.

Chlamydia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

- Total Prevalence of Chlamydia
- Prevalent Cases of Chlamydia by severity
- Gender-specific Prevalence of Chlamydia
- Diagnosed Cases of Episodic and Chronic Chlamydia

Download the report to understand which factors are driving Chlamydia epidemiology trends @ [Chlamydia Epidemiology Forecast](#)

Chlamydia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chlamydia market or expected to get launched during the study period. The analysis covers Chlamydia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Chlamydia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Chlamydia Therapies and Companies

- EVO100: Evofem Biosciences
- Chlamydia Infection blockers (CIBs): QureTechBio
- VPI-201: Vault Pharma
- Salmonella-Based Vaccine: Aeterna Zentaris
- Rifalazil: ActivBiotics Pharma, LLC
- PRO 2000/5: Endo Pharma

Chlamydia Market Strengths

- Chlamydia is by far the most common reportable STI, with a high rate of incidence that is likely to further increase in the future, increasing the need for treatment
- Updated treatment guidelines and screening recommendations
- Diagnosis has become fast and easy with the development of highly sensitive and specific cost-effective diagnostic techniques
- A multitude of therapies like chlamydia infection blockers (CIBs), VPI-201, ABX196, and others are in initial phases of development that will pave the way for the future market

Chlamydia Unmet Needs

- Early disease diagnosis
- Vaccine
- Challenges in treatment
- Social stigma and patient awareness

Scope of the Chlamydia Market Report

- Study Period: 2019-2032
- Coverage: 7MM
- Chlamydia Companies: Evofem Biosciences, QureTechBio, Vault Pharma, Aeterna Zentaris, ActivBiotics Pharma, LLC, Endo Pharma, and others
- Chlamydia Therapies: EVO100, Chlamydia Infection blockers (CIBs), VPI-201, Salmonella-Based Vaccine, Rifalazil, PRO 2000/5, and others
- Chlamydia Therapeutic Assessment: Chlamydia current marketed and Chlamydia emerging therapies
- Chlamydia Market Dynamics: Chlamydia market drivers and Chlamydia market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
- Chlamydia Unmet Needs, KOL's views, Analyst's views, Chlamydia Market Access and Reimbursement

Table of Contents

1. Chlamydia Market Report Introduction
2. Executive Summary for Chlamydia
3. SWOT analysis of Chlamydia
4. Chlamydia Patient Share (%) Overview at a Glance
5. Chlamydia Market Overview at a Glance
6. Chlamydia Disease Background and Overview
7. Chlamydia Epidemiology and Patient Population
8. Country-Specific Patient Population of Chlamydia
9. Chlamydia Current Treatment and Medical Practices
10. Chlamydia Unmet Needs
11. Chlamydia Emerging Therapies
12. Chlamydia Market Outlook

13. Country-Wise Chlamydia Market Analysis (2019-2032)
14. Chlamydia Market Access and Reimbursement of Therapies
15. Chlamydia Market Drivers
16. Chlamydia Market Barriers
17. Chlamydia Appendix
18. Chlamydia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

To know more about Chlamydia companies working in the treatment market, visit @ [Chlamydia Infections Market Drivers and Barriers](#)

Yash Bhardwaj
DelveInsight
+91 9650213330

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

[Instagram](#)

[YouTube](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/697076775>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.